Pendopharm signs distribution agreement with Ascendis Pharma for TransCon PTH in Canada

  • Pendopharm, a division of Pharmascience, said it has signed an exclusive distribution agreement with Denmark-based biopharmaceutical company Ascendis Pharma A/S (ASND).
  • Under the terms of the agreement, Pendopharm is responsible for regulatory approval and commercialization of Ascendis’ hypoparathyroidism treatment TransCon PTH in Canada.
  • Financial terms of the agreement are not disclosed.
  • Source: Press Release